PRPO: AI 评分 57/100 — AI 分析 (4月 2026)

Precipio, Inc. is a healthcare solutions company specializing in diagnostic products and services, particularly in blood cancer testing. Their proprietary technologies like ICE-COLD PCR aim to improve diagnostic accuracy and sensitivity.

Key Facts: Price: $23.74 AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Precipio, Inc. revolutionizes cancer diagnostics with innovative technologies like ICE-COLD PCR and HemeScreen, offering enhanced sensitivity and precision in blood cancer testing, positioning them as a key player in personalized medicine and bio-pharma collaborations within the healthcare sector.

PRPO是做什么的？

Precipio, Inc., headquartered in New Haven, Connecticut, is a healthcare solutions company focused on transforming cancer diagnostics through innovative technologies and services. Founded with the mission to improve diagnostic accuracy and patient outcomes, Precipio has evolved into a provider of specialized diagnostic solutions, particularly in the field of hematological malignancies. The company's core offerings include diagnostic blood cancer testing services, leveraging proprietary technologies such as IV-Cell, a cell culture media enabling simultaneous culturing of four hematopoietic cell lineages, and HemeScreen, a suite of genetic diagnostic panels designed for comprehensive analysis of blood cancers. A key differentiator is their patented ICE-COLD PCR technology, which significantly enhances the sensitivity of molecular-based tests, allowing for earlier and more accurate detection of cancer. Precipio also offers COVID-19 antibody tests, demonstrating its adaptability to emerging healthcare needs. The company sells ICE-COLD-PCR technology kits to bio-pharma customers, further expanding its revenue streams and market reach. Through collaborations with leading academic institutions specializing in cancer research, diagnostics, and treatment, Precipio remains at the forefront of innovation in the diagnostic space, solidifying its position as a valuable partner in advancing personalized medicine.

PRPO的投资论点是什么？

Precipio, Inc. presents a notable market position due to its innovative diagnostic technologies and strategic focus on blood cancer testing. The company's proprietary ICE-COLD PCR technology offers a significant advantage in terms of test sensitivity, potentially driving increased adoption and revenue growth. With a gross margin of 47.5%, Precipio has demonstrated its ability to generate profitable revenue from its diagnostic services and technology sales. Key growth catalysts include expanding collaborations with academic institutions and bio-pharma companies, as well as increasing market penetration of HemeScreen and IV-Cell products. While the company currently operates with a negative profit margin of -5.8% and a P/E ratio of -26.19, strategic partnerships and revenue growth from increased adoption of their technologies could drive profitability. The company's relatively small market cap of $0.04 billion suggests significant upside potential if Precipio can successfully execute its growth strategy and capitalize on the increasing demand for advanced diagnostic solutions.

PRPO在哪个行业运营？

Precipio, Inc. operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in personalized medicine and increasing demand for accurate and early disease detection. The market for cancer diagnostics is particularly robust, fueled by rising cancer incidence rates and the need for more effective treatment strategies. Precipio's focus on blood cancer testing positions it within a specialized segment of this market. Competitors include companies like APUS, INTS, ITRM, LDDD, and MLSS, each offering various diagnostic solutions. Precipio differentiates itself through its proprietary technologies, such as ICE-COLD PCR, which enhances test sensitivity and provides a competitive edge in the market.

Medical - Diagnostics & Research

Healthcare

PRPO有哪些增长机遇？

Expanding ICE-COLD PCR Technology Sales: Precipio has the opportunity to significantly increase revenue by expanding the sales of its ICE-COLD PCR technology kits to bio-pharma companies. The market for advanced PCR technologies is growing, driven by the increasing demand for highly sensitive diagnostic tools. By targeting bio-pharma companies involved in drug development and clinical trials, Precipio can capitalize on this trend and establish ICE-COLD PCR as a standard in molecular diagnostics. This expansion could generate substantial revenue growth within the next 2-3 years.
Increasing HemeScreen Market Penetration: HemeScreen, Precipio's suite of genetic diagnostic panels for blood cancers, represents a significant growth opportunity. By increasing market penetration through targeted marketing and sales efforts, Precipio can capture a larger share of the blood cancer diagnostics market. The increasing prevalence of blood cancers and the growing demand for personalized treatment strategies will drive demand for HemeScreen. Success in this area could lead to significant revenue growth over the next 3-5 years.
Strategic Collaborations with Academic Institutions: Precipio's collaborations with academic institutions specializing in cancer research, diagnostics, and treatment provide a strong foundation for future growth. By expanding these collaborations, Precipio can gain access to cutting-edge research, develop new diagnostic products, and strengthen its market position. These partnerships can also lead to increased adoption of Precipio's technologies and services within the academic community, driving revenue growth and enhancing the company's reputation over the long term.
Geographic Expansion of Diagnostic Services: Precipio can pursue geographic expansion of its diagnostic services, particularly in regions with high unmet needs for advanced cancer diagnostics. By establishing partnerships with hospitals and clinics in new markets, Precipio can extend its reach and increase its customer base. This expansion could involve offering remote testing services or establishing local laboratories, depending on the specific market conditions. Successful geographic expansion could significantly increase Precipio's revenue and market share within the next 3-5 years.
Development of New Diagnostic Assays: Precipio can leverage its expertise in molecular diagnostics to develop new diagnostic assays for other types of cancer and diseases. By expanding its product portfolio, Precipio can diversify its revenue streams and reduce its reliance on blood cancer testing. This could involve developing new PCR-based assays, as well as exploring other diagnostic technologies such as next-generation sequencing and liquid biopsy. Successful development and commercialization of new diagnostic assays could drive significant revenue growth over the long term.

Gross Margin of 47.5% demonstrates the potential for profitability in their diagnostic services and technology sales.
ICE-COLD PCR technology enhances the sensitivity of molecular-based tests, offering a competitive advantage.
Collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, positioning Precipio at the forefront of innovation.
HemeScreen, a suite of genetic diagnostic panels, provides comprehensive analysis of blood cancers.
Market Cap of $0.04B indicates significant growth potential if Precipio successfully executes its growth strategy.

PRPO提供哪些产品和服务？

Provides diagnostic blood cancer testing services.
Offers IV-Cell, a proprietary cell culture media.
Offers HemeScreen, a suite of genetic diagnostic panels.
Provides ICE-COLD PCR, a patented specimen technology for increased test sensitivity.
Sells ICE-COLD-PCR technology kits to bio-pharma customers.
Offers COVID-19 antibody tests.

PRPO如何赚钱？

Sales of diagnostic products and reagents, including IV-Cell and HemeScreen.
Revenue from diagnostic testing services, particularly in blood cancer diagnostics.
Sales of ICE-COLD-PCR technology kits to bio-pharma companies.
Collaborations with academic institutions for research and development.

Hospitals and clinics requiring diagnostic testing services.
Academic institutions involved in cancer research.
Bio-pharma companies utilizing ICE-COLD PCR technology for drug development.
Patients seeking diagnostic testing for blood cancers.

Proprietary ICE-COLD PCR technology provides enhanced test sensitivity.
Specialized expertise in blood cancer diagnostics.
Collaborations with leading academic institutions.
HemeScreen diagnostic panels offer comprehensive analysis.

什么因素可能推动PRPO股价上涨？

Ongoing: Expansion of collaborations with academic institutions for research and development.
Ongoing: Increasing market penetration of HemeScreen diagnostic panels.
Upcoming: Potential FDA approval of new diagnostic assays developed by Precipio.
Ongoing: Sales growth of ICE-COLD PCR technology kits to bio-pharma companies.

PRPO的主要风险是什么？

Ongoing: Competition from larger diagnostic companies with greater resources.
Potential: Regulatory changes impacting the approval and reimbursement of diagnostic tests.
Potential: Economic downturn affecting healthcare spending and demand for diagnostic services.
Potential: Technological advancements rendering existing products obsolete.
Ongoing: The company's negative profit margin poses a risk to its financial sustainability.

PRPO的核心优势是什么？

Proprietary ICE-COLD PCR technology.
Specialized focus on blood cancer diagnostics.
Collaborations with academic institutions.
Comprehensive HemeScreen diagnostic panels.

PRPO的劣势是什么？

Negative profit margin.
Small market capitalization.
Limited geographic reach.
Reliance on a limited number of products.

PRPO有哪些机遇？

Expanding ICE-COLD PCR technology sales.
Increasing HemeScreen market penetration.
Developing new diagnostic assays.
Geographic expansion of diagnostic services.

PRPO面临哪些威胁？

Competition from larger diagnostic companies.
Regulatory changes impacting diagnostic testing.
Economic downturn affecting healthcare spending.
Technological advancements rendering existing products obsolete.

PRPO的竞争对手是谁？

Agenus Inc. — Focuses on immuno-oncology products. — (APUS)
Intellicheck, Inc. — Provides identity authentication solutions. — (INTS)
Iterum Therapeutics plc — Develops anti-infectives. — (ITRM)
Longboard Pharmaceuticals, Inc. — Develops therapeutics for neurological diseases. — (LDDD)
Milestone Scientific Inc. — Develops computer-controlled drug delivery systems. — (MLSS)

Key Metrics

Price: $23.74 (-0.34%)
Market Cap: $36.5M
Volume: 5,310
MoonshotScore: 57/100

Company Profile

CEO: Ilan Danieli
Headquarters: New Haven, CT, US
Employees: 54
Founded: 2017

AI Insight

Precipio, Inc. is a healthcare solutions company that provides diagnostic products, reagents, and services in the United States. They offer diagnostic blood cancer testing services and sell ICE-COLD-PCR technology kits to bio-pharma customers.

常见问题

What does Precipio, Inc. do?

Precipio, Inc. is a healthcare solutions company that specializes in diagnostic products, reagents, and services, primarily focused on blood cancer testing. The company offers a range of diagnostic solutions, including IV-Cell, a proprietary cell culture media, HemeScreen, a suite of genetic diagnostic panels, and ICE-COLD PCR, a patented technology that enhances the sensitivity of molecular-based tests. Precipio sells ICE-COLD-PCR technology kits to bio-pharma customers and collaborates with academic institutions to advance cancer research and diagnostics. Their business model revolves around providing innovative diagnostic tools and services to improve patient outcomes in the field of hematological malignancies.

Is PRPO stock a good buy?

PRPO stock presents a speculative investment opportunity with high potential upside and significant risks. The company's innovative ICE-COLD PCR technology and focus on blood cancer diagnostics offer a competitive advantage. However, the company's negative profit margin and small market capitalization raise concerns about its financial stability. Investors should carefully consider Precipio's growth potential, technological advantages, and financial risks before investing. Monitoring key metrics such as revenue growth, gross margin, and progress in expanding collaborations will be crucial in assessing the investment's viability. A positive shift towards profitability would be a strong indicator of future success.

What are the main risks for PRPO?

Precipio faces several key risks, including intense competition from larger diagnostic companies with greater resources, potential regulatory changes impacting the approval and reimbursement of diagnostic tests, and the risk of an economic downturn affecting healthcare spending. Additionally, technological advancements could render Precipio's existing products obsolete, requiring continuous innovation and investment in research and development. The company's current negative profit margin also poses a significant risk to its financial sustainability, requiring effective cost management and revenue growth strategies to achieve profitability. Successfully navigating these risks will be crucial for Precipio's long-term success.